TLSI
TriSalus Life Sciences, Inc.Company with tickers: TLSI, TLSIW
CIK
1826667
CUSIP
89680M101
Shares Outstanding
61,416,535
13F Activity (30d)
53 filings
50 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $8,899,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | $7,669,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Expenses | — | ||||
| Research & Development | $3,216,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-8,411,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $1,539,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $0.03 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |